Figure 2From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapyLocal, regional, and distant control rates as differentiated by SUV max . A: Local control differences between SUVmax categories, p= 0.256; B: Regional control differences between SUVmax categories, p= 0.131; C: Distant control differences between SUVmax categories, p= 0.371.Back to article page